DK2376499T3 - 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaencitratsalt - Google Patents
11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaencitratsalt Download PDFInfo
- Publication number
- DK2376499T3 DK2376499T3 DK09788621T DK09788621T DK2376499T3 DK 2376499 T3 DK2376499 T3 DK 2376499T3 DK 09788621 T DK09788621 T DK 09788621T DK 09788621 T DK09788621 T DK 09788621T DK 2376499 T3 DK2376499 T3 DK 2376499T3
- Authority
- DK
- Denmark
- Prior art keywords
- salt
- shows
- hci
- batch
- ray diffraction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/22—Tricarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
- C07D201/02—Preparation of lactams
- C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Saccharide Compounds (AREA)
Claims (13)
1. Citratsalt af ll-(2-pyrrolidin-l-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6). 1(8,12)]heptacosa-l (25),2(26),3,5,8,10,12(27),16,21,23-decaen.
2. Salt ifølge krav 1, hvor saltet er krystallinsk.
3. Salt ifølge krav 1 eller 2, hvor saltet er l:l-saltet.
4. Salt ifølge et hvilket som helst af kravene 1 til 3 der viser på røntgendiffraktion en top på 2-theta-skalaen ved 22,4°±0,5°.
5. Salt ifølge krav 4 der også viser på røntgendiffraktion toppe på 2-theta-skalaen ved 10,2°±0,5° og 15,7°±0,5°.
6. Salt ifølge et hvilket som helst af kravene 1 til 5 der viser på røntgendiffraktion mindst fire toppe på 2-theta-skalaen valgt fra gruppen bestående af 7,8°±0,5°, 10,2°±0,5°, 14,2°±0,5°, 15,7°±0,5°, 16,8°±0,5°, 21,4°±0,5°, og 22,4°±0,5°.
7. Salt ifølge krav 6 der viser på røntgendiffraktion mindst 6 toppe på 2-theta-skalaen valgt fra gruppen bestående af 7,8°±0,5°, 10,2°±0,5°, 14,2°±0,5°, 15,7°±0,5°, 16,8°±0,5°, 21,4°±0,5°, og 22,4°±0,5°.
8. Salt ifølge krav 6 der viser på røntgendiffraktion toppe på 2-theta-skalaen ved 7,8°±0,5°, 10,2°±0,5°, 14,2°±0,5°, 15,7°±0,5°, 16,8°±0,5°, 21,4°±0,5°, og 22,4°±0,5°.
9. Salt ifølge krav 8 der også viser på røntgendiffraktion toppe på 2-theta-skalaen ved 10,9°±0,5°, 17,1°±0,5°, 23,3°±0,5°, 25,1°±0,5°, 25.8°±0,5°, og 27,5°±0,5°.
10. Salt ifølge krav 9 der også viser på røntgendiffraktion toppe på 2-theta-skalaen ved 7,2°±0,5°, 17,6°±0,5°, 18,5°±0,5°, 18,7°±0,5°, 20,7°±0,5°, 23,1°±0,5°, 24,2°±0,5°, 26,2°±0,5°, 26,9°±0,5°, 28,7°±0,5°, 29,3°±0,5°, 31,0°±0,5°, 32,4°±0,5°, 37,3°±0,5°, 38,6°±0,5°, 39,9°±0,5° og 41,6°±0,5°.
11. Farmaceutisk sammensætning omfattende et salt ifølge et hvilket som helst af kravene 1 til 10.
12. Salt ifølge et hvilket som helst af kravene 1 til 10 til anvendelse i behandling eller forebyggelse af en proliferativ lidelse.
13. Salt til anvendelse ifølge krav 12, hvor den proliferative lidelse er cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12166808P | 2008-12-11 | 2008-12-11 | |
| PCT/SG2009/000473 WO2010068181A1 (en) | 2008-12-11 | 2009-12-09 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2376499T3 true DK2376499T3 (da) | 2015-05-04 |
Family
ID=41666397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09788621T DK2376499T3 (da) | 2008-12-11 | 2009-12-09 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19,3,1,1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaencitratsalt |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8980873B2 (da) |
| EP (1) | EP2376499B1 (da) |
| JP (1) | JP5669748B2 (da) |
| KR (1) | KR101729918B1 (da) |
| CN (1) | CN102282148B (da) |
| AR (2) | AR074724A1 (da) |
| AU (1) | AU2009325147B2 (da) |
| BR (1) | BRPI0922736B1 (da) |
| CA (1) | CA2746058C (da) |
| DK (1) | DK2376499T3 (da) |
| ES (1) | ES2536558T3 (da) |
| HK (1) | HK1161877A1 (da) |
| HR (1) | HRP20150428T1 (da) |
| IL (3) | IL213418A0 (da) |
| MX (1) | MX2011006206A (da) |
| MY (1) | MY160005A (da) |
| NZ (1) | NZ593223A (da) |
| PL (1) | PL2376499T3 (da) |
| PT (1) | PT2376499E (da) |
| RU (1) | RU2527970C2 (da) |
| SG (1) | SG171907A1 (da) |
| TW (1) | TWI449705B (da) |
| WO (1) | WO2010068181A1 (da) |
| ZA (1) | ZA201104032B (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5669748B2 (ja) | 2008-12-11 | 2015-02-12 | シーティーアイ・バイオファーマ・コーポレーションＣＴＩ ＢｉｏＰｈａｒｍａ Ｃｏｒｐ． | １１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩 |
| US8987243B2 (en) * | 2008-12-11 | 2015-03-24 | Cti Biopharma Corp. | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt |
| KR101673979B1 (ko) | 2012-04-13 | 2016-11-08 | 리안윤강 진강 해신 파머수티컬 코. 엘티디. | 화합물 jk12a 및 그 제조 |
| CN105061467B (zh) * | 2015-08-28 | 2017-08-25 | 苏州立新制药有限公司 | 一种帕克替尼的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
| US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
| JP4137645B2 (ja) * | 2001-05-14 | 2008-08-20 | ファイザー・プロダクツ・インク | ５，８，１４−トリアザテトラシクロ［１０．３．１．０２，１１．０４，９］−ヘキサデカ−２（１１），３，５，７，９−ペンタンのクエン酸塩及びその医薬組成物 |
| US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
| ES2258652T3 (es) * | 2001-11-29 | 2006-09-01 | Pfizer Products Inc. | Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos. |
| WO2007058628A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Heteroalkyl linked pyrimidine derivatives |
| JP5669748B2 (ja) | 2008-12-11 | 2015-02-12 | シーティーアイ・バイオファーマ・コーポレーションＣＴＩ ＢｉｏＰｈａｒｍａ Ｃｏｒｐ． | １１−（２−ピロリジン−１−イル−エトキシ）−１４，１９−ジオキサ−５，７，２６−トリアザ−テトラシクロ［１９．３．１．１（２，６）．１（８，１２）］ヘプタコサ−１（２５），２（２６），３，５，８，１０，１２（２７），１６，２１，２３−デカエンクエン酸塩 |
-
2009
- 2009-12-09 JP JP2011540664A patent/JP5669748B2/ja active Active
- 2009-12-09 WO PCT/SG2009/000473 patent/WO2010068181A1/en active Application Filing
- 2009-12-09 KR KR1020117015738A patent/KR101729918B1/ko active IP Right Grant
- 2009-12-09 CA CA2746058A patent/CA2746058C/en active Active
- 2009-12-09 PL PL09788621T patent/PL2376499T3/pl unknown
- 2009-12-09 EP EP09788621.2A patent/EP2376499B1/en active Active
- 2009-12-09 PT PT97886212T patent/PT2376499E/pt unknown
- 2009-12-09 MY MYPI2011002647A patent/MY160005A/en unknown
- 2009-12-09 US US13/133,297 patent/US8980873B2/en active Active
- 2009-12-09 SG SG2011040060A patent/SG171907A1/en unknown
- 2009-12-09 MX MX2011006206A patent/MX2011006206A/es active IP Right Grant
- 2009-12-09 BR BRPI0922736-9A patent/BRPI0922736B1/pt active IP Right Grant
- 2009-12-09 CN CN200980150325.5A patent/CN102282148B/zh active Active
- 2009-12-09 DK DK09788621T patent/DK2376499T3/da active
- 2009-12-09 RU RU2011126173/04A patent/RU2527970C2/ru active
- 2009-12-09 ES ES09788621.2T patent/ES2536558T3/es active Active
- 2009-12-09 AU AU2009325147A patent/AU2009325147B2/en active Active
- 2009-12-09 NZ NZ593223A patent/NZ593223A/xx unknown
- 2009-12-11 TW TW098142605A patent/TWI449705B/zh active
- 2009-12-11 AR ARP090104834A patent/AR074724A1/es not_active Application Discontinuation
-
2011
- 2011-05-31 ZA ZA2011/04032A patent/ZA201104032B/en unknown
- 2011-06-06 IL IL213418A patent/IL213418A0/en unknown
-
2012
- 2012-03-08 HK HK12102375.7A patent/HK1161877A1/xx unknown
-
2015
- 2015-02-13 US US14/621,726 patent/US9624242B2/en active Active
- 2015-04-20 HR HRP20150428TT patent/HRP20150428T1/hr unknown
-
2017
- 2017-01-26 IL IL250310A patent/IL250310A0/en unknown
-
2019
- 2019-03-20 AR ARP190100701A patent/AR114133A2/es unknown
-
2021
- 2021-12-26 IL IL289379A patent/IL289379A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9624242B2 (en) | 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | |
| DK2376500T3 (da) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt | |
| US20230295121A1 (en) | Solid forms of pralsetinib | |
| US9062074B2 (en) | (9E)-15-(2-pyrrolidin-1-yl-ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2.5).1(14,18)]hexacosa-1(24),2,4,9,14,16,18(26),20,22-nonaene citrate salt | |
| WO2014147504A2 (en) | Process for preparation of 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms | |
| EP2922838B1 (en) | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} . | |
| AU2016304852A1 (en) | Processes for preparing an FGFR inhibitor | |
| CZ305096B6 (cs) | Pevná forma Ivabradin hydrochloridu a (S)-mandlové kyseliny a její farmaceutická kompozice | |
| WO2016004911A1 (en) | A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition | |
| KR20220129495A (ko) | 단백질 키나제 억제제로서의 헤테로고리 화합물의 결정형 | |
| WO2011039670A1 (en) | Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole) | |
| AU2016210725A1 (en) | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |